Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Centre Hospitalier Universitaire de Besancon
University of Pittsburgh
Coherus Oncology, Inc.
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Delfi Diagnostics Inc.
Genentech, Inc.
Institut Bergonié
Arbeitsgemeinschaft medikamentoese Tumortherapie
Rutgers, The State University of New Jersey
Taproot Health
Astellas Pharma Inc
Astellas Pharma Inc
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DxTerity Diagnostics
Cedars-Sinai Medical Center
Sanguine Biosciences
Celldex Therapeutics
Corvus Pharmaceuticals, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Barbara Ann Karmanos Cancer Institute
Janssen Research & Development, LLC
Quadriga Biosciences, Inc.
Exact Sciences Corporation
Roswell Park Cancer Institute
Syndax Pharmaceuticals
Pfizer
Weill Medical College of Cornell University
Novartis
Syndax Pharmaceuticals
Fate Therapeutics
Osaka University
Alliance for Clinical Trials in Oncology
University of Zurich
University of Chicago
National Institutes of Health Clinical Center (CC)
Stanford University
Amgen
Butler Hospital
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
GlaxoSmithKline
Duke University
Wake Forest University Health Sciences
Roswell Park Cancer Institute
GlaxoSmithKline